secwatch / observer
8-K filed January 13, 2026, 6:59 PM ET ticker CODX CIK 0001692415
other material confidence high sentiment negative materiality 0.80

Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14

Co-Diagnostics, Inc.

item 3.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001493152-26-001971
form_type
8-K
ticker
CODX
cik
0001692415
company_name
Co-Diagnostics, Inc.
filed_at
2026-01-13T23:59:59+00:00
discovered_at
2026-05-14T18:02:35.908971+00:00
generated_at
2026-05-16T10:40:55.131906+00:00
sec_items
["3.01"]
event_type
other_material
sentiment
negative
materiality_score
0.8
calibrated_materiality_score
0.8
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001493152-26-001971
json_url
https://secwatch.observer/filing/0001493152-26-001971.json
markdown_url
https://secwatch.observer/filing/0001493152-26-001971.md
text_url
https://secwatch.observer/filing/0001493152-26-001971.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/0001493152-26-001971-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1692415/000149315226001971/form8-k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

261b568cd7b2030ed2d81edf468a4a8fc6e8b314

Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

ADTX

Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11

Aditxt, Inc. May 29, 2026, 4:21 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further

Filing page SEC filing

LIMN

Liminatus Pharma receives Nasdaq delisting notice; appeals filed

Liminatus Pharma, Inc. May 27, 2026, 4:30 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Mark

Filing page SEC filing

TNON

Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity

Tenon Medical, Inc. May 22, 2026, 5:15 PM ET other_material Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

May 21, 2026, Tenon Medical, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying the Company that it is no longer in compliance with the

Filing page SEC filing

AGAE

AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K

Allied Gaming & Entertainment Inc. May 21, 2026, 9:40 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

May 19, 2026, All In FutureTech Alliance, Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of

Filing page SEC filing

PMI

Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices

Picard Medical, Inc. May 21, 2026, 4:15 PM ET other_material Items 2.02, 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

reviously disclosed, on May 8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together with the May 15 Notice, the “ Notices ”). In connection with the

Filing page SEC filing

XXI

Tether International acquires SoftBank's stake in Twenty One Capital; board members resign

Twenty One Capital, Inc. May 20, 2026, 8:49 AM ET other_material Items 1.02, 3.01, 5.02, 8.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

o independent directors, the minimum number required during the transition period for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual

Filing page SEC filing

SOPA

Society Pass receives Nasdaq delisting notice after filing Chapter 11 bankruptcy

SOCIETY PASS INCORPORATED. May 20, 2026, 6:05 AM ET other_material Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

May 14, 2026, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq had determined to delist the Company’s common stock, par value $0.0001 per share (the

Filing page SEC filing

BTM

Bitcoin Depot files Chapter 11; Nasdaq to suspend BTM stock and warrants on May 26

Bitcoin Depot Inc. May 19, 2026, 4:01 PM ET other_material Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: other_material similar materiality

This filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

Comparable filing

May 18, 2026, the Company received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Debtors’ commencement of the Chapter 1

Filing page SEC filing

Source: SEC EDGAR
accession 0001493152-26-001971
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.